SCHEMBL14634249

SCHEMBL14634249

CNc1nc(Nc2cc(OC)cc(S(C)(=O)=O)c2)ncc1-c1n[nH]c2cc(F)c(F)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK9 P50750 5/20 0.40
CDK2 P24941 4/20 0.40
LRRK2 Q5S007 5/20 0.38
SYK P43405 3/20 0.38
MAP2K4 P45985 1/20 0.37
JAK2 O60674 2/20 0.37
JAK1 P23458 2/20 0.37
JAK3 P52333 2/20 0.37
PTGS2 P35354 1/20 0.36
GAK O14976 1/20 0.36
AURKA O14965 2/20 0.36
CCNT1 O60563 2/20 0.36
CCNE1 P24864 2/20 0.36
IGF1R P08069 1/20 0.36
MAP4K4 O95819 1/20 0.35
ABL1 P00519 1/20 0.35
LCK P06239 1/20 0.35
MET P08581 1/20 0.35
PDGFRB P09619 1/20 0.35
FGFR1 P11362 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14633947 0.95 JAK1 (0.39) CDK9CDK2LRRK2SYKMAP2K4
SCHEMBL14634222 0.90 RIPK2 (0.43) CDK9CDK2LRRK2SYKMAP2K4
SCHEMBL2465754 0.90 CDK9 (0.40) CDK9CDK2LRRK2SYKMAP2K4
SCHEMBL14634057 0.89 CDK2 (0.38) CDK9CDK2LRRK2SYKJAK2
SCHEMBL14633760 0.88 CCNT1 (0.37) CDK9CDK2LRRK2SYKMAP2K4
SCHEMBL14634215 0.87 CDK2 (0.39) CDK9CDK2LRRK2SYKMAP2K4
SCHEMBL14633563 0.86 CDK2 (0.39) CDK9CDK2LRRK2SYKMAP2K4
SCHEMBL14633989 0.86 SYK (0.42) CDK9CDK2LRRK2SYKMAP2K4
SCHEMBL2467714 0.85 JAK1 (0.40) CDK9CDK2LRRK2SYKMAP2K4
SCHEMBL14634045 0.84 JAK1 (0.38) CDK9CDK2LRRK2SYKMAP2K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS MAP3K19, MAP3K1, MAP3K20 CDK9 55/4885CDK2 22/4885LRRK2 487/4885
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS CDK2, MAP3K19, MAP3K1 CDK9 45/4885CDK2 1/4885LRRK2 599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.